The combination of midkine inhibitor with Lenvatinib amplifies the suppression of hepatocellular carcinoma DOI

Xue Chen,

Shujun Guo,

Qilin Meng

et al.

IUBMB Life, Journal Year: 2025, Volume and Issue: 77(5)

Published: May 1, 2025

Abstract Hepatocellular carcinoma (HCC) accounts for 75%–85% of primary liver cancer cases globally. HCC patients have a poor prognosis because tumor metastasis and medication resistance; thus, novel therapy targets techniques are needed. By using the Kaplan–Meier plotter database, we identified strong association between midkine (MDK) mortality validated its high expression in numerous cell lines. In vitro, MDK down‐regulation decreased growth macrophage M2‐type polarization, whereas presence factor led to an increase these processes. Combined with first‐line chemotherapeutic agent HCC, Lenvatinib, zebrafish experiments showed that inhibitor iMDK inhibited intersegmental vessels subintestinal vessels, while also mitigating pericardial edema side effect. subcutaneous mouse model, combination Lenvatinib growth, angiogenesis, infiltration. These results indicate represents promising therapeutic target HCC. Furthermore, enhances inhibition, thereby presenting option.

Language: Английский

The combination of midkine inhibitor with Lenvatinib amplifies the suppression of hepatocellular carcinoma DOI

Xue Chen,

Shujun Guo,

Qilin Meng

et al.

IUBMB Life, Journal Year: 2025, Volume and Issue: 77(5)

Published: May 1, 2025

Abstract Hepatocellular carcinoma (HCC) accounts for 75%–85% of primary liver cancer cases globally. HCC patients have a poor prognosis because tumor metastasis and medication resistance; thus, novel therapy targets techniques are needed. By using the Kaplan–Meier plotter database, we identified strong association between midkine (MDK) mortality validated its high expression in numerous cell lines. In vitro, MDK down‐regulation decreased growth macrophage M2‐type polarization, whereas presence factor led to an increase these processes. Combined with first‐line chemotherapeutic agent HCC, Lenvatinib, zebrafish experiments showed that inhibitor iMDK inhibited intersegmental vessels subintestinal vessels, while also mitigating pericardial edema side effect. subcutaneous mouse model, combination Lenvatinib growth, angiogenesis, infiltration. These results indicate represents promising therapeutic target HCC. Furthermore, enhances inhibition, thereby presenting option.

Language: Английский

Citations

0